Nanjing-based Chinese biotech developing antibody and bispecific-antibody therapeutics for cancer and autoimmune disease.
Nanjing-based Chinese biotech developing antibody and bispecific-antibody therapeutics for cancer and autoimmune disease.
Has no marketed drug, so it is paid through licensing: partners hand over an upfront fee and later milestone payments as a drug passes trial stages, while the rest of its funding comes from selling shares. Its bispecific candidates, which bind two targets at once, are what partners are buying.
Moat: narrow (IP / patents). Proprietary bispecific-antibody platform, but early-stage pipeline with unproven commercial products.
Headquarters: Nanjing, China · Employees: 244
Size Nanjing Leads Biolabs (9887.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $764M, the 647th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$30.68 on 18 Nov 2026.
Performance Over six months the shares fell 50.0%, against -12.2% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 19 in its peer set.
Growth The operating margin is -107.8% (peer median -90.3%).
Valuation It trades at 21.1× enterprise value to sales against a peer median of 6.6× (4th most expensive of 17).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$235M | HK$192M | HK$0 | HK$9.80M | HK$0 |
| Revenue growth | — | — | -100% | — | — |
| Gross profit | n/a | n/a | -HK$28.2M | -HK$20.1M | -HK$20.2M |
| EBITDA | -HK$229M | -HK$188M | -HK$268M | -HK$264M | -HK$223M |
| Net income | -HK$302M | -HK$229M | -HK$327M | -HK$400M | -HK$327M |
| Free cash flow | n/a | -HK$184M | -HK$138M | -HK$233M | -HK$84.7M |
| Capital expenditure | n/a | HK$11.3M | HK$3.23M | HK$13.0M | HK$33.9M |
| Total debt | n/a | HK$312M | HK$284M | HK$1.51B | HK$1.35B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Nanjing Leads Biolabs 9887.HK | $764M | -50% | n/a | -108% | 21.1× | n/a |
| Akeso 9926.HK | $7.01B | -48% | +42% | -25% | 12.9× | n/a |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% |
| Alphamab Oncology 9966.HK | $666M | -38% | -32% | -38% | 6.7× | n/a |
| RemeGen 9995.HK | $6.07B | -28% | +293% | 61% | 4.4× | -6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9887.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -28.6% | -6.2% | 2nd lowest of 21 |
| 6-month return | -50.0% | -12.2% | 3rd lowest of 19 |
| Distance from 52-week high | -68.5% | -44.9% | lowest of 21 |
| Operating margin | -107.8% | -90.3% | 9th highest of 17 |
| EV / Sales | 21.1× | 6.6× | 4th most expensive of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | 12,169.8× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | 3.3× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 4.4× | 7.8% | +2.4% |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | 1.9× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | 4.1× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | 8.2× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 6.6× | n/a | n/a |